Beam Therapeutics Inc. (NASDAQ:BEAM) has seen 0.64 million shares traded in the last trading session. The company, currently valued at $7.57B, closed the last trade at $112.52 per share which meant it lost -$1.55 on the day or -1.36% during that session. The BEAM stock price is -23.11% off its 52-week high price of $138.52 and 81.12% above the 52-week low of $21.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.7 million shares traded. The 3-month trading volume is 789.69K shares.
The consensus among analysts is that Beam Therapeutics Inc. (BEAM) is an Overweight stock at the moment, with a recommendation rating of 2.10. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 8 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.65.
Beam Therapeutics Inc. (NASDAQ:BEAM) trade information
Sporting -1.36% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the BEAM stock price touched $112.52 or saw a rise of 3.42%. Year-to-date, Beam Therapeutics Inc. shares have moved 37.82%, while the 5-day performance has seen it change 5.57%. Over the past 30 days, the shares of Beam Therapeutics Inc. (NASDAQ:BEAM) have changed 1.68%. Short interest in the company has seen 5.16 million shares shorted with days to cover at 8.25.
Wall Street analysts have a consensus price target for the stock at $119.17, which means that the shares’ value could jump 5.58% from current levels. The projected low price target is $85.00 while the price target rests at a high of $150.00. In that case, then, we find that the current price level is -33.31% off the targeted high while a plunge would see the stock lose 24.46% from current levels.
Beam Therapeutics Inc. (BEAM) estimates and forecasts
Figures show that Beam Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 57.86% over the past 6 months, with this year growth rate of -122.26%, compared to 7.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 5.80% and 1.40% for the next quarter. Revenue growth from the last financial year stood is estimated to be 10,358.30%.
6 have an estimated revenue figure of $9.58 million for the next quarter concluding in Sep 2021.
Beam Therapeutics Inc. is expected to release its next earnings report on March 15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Beam Therapeutics Inc. (NASDAQ:BEAM)’s Major holders
Insiders own 1.93% of the company shares, while shares held by institutions stand at 79.64% with a share float percentage of 81.21%. Investors are also buoyed by the number of investors in a company, with Beam Therapeutics Inc. having a total of 301 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 7.69 million shares worth more than $989.17 million. As of Jun 29, 2021, FMR, LLC held 11.58% of shares outstanding.
The other major institutional holder is ARK Investment Management, LLC, with the holding of over 6.46 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $831.64 million and represent 9.74% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. As of Jun 29, 2021, the former fund manager holds about 7.06% shares in the company for having 4.69 million shares of worth $603.03 million while later fund manager owns 1.77 million shares of worth $227.41 million as of Jun 29, 2021, which makes it owner of about 2.66% of company’s outstanding stock.